Pharmacokinetics and safety of cefamandole in newborn infants.
Cefamandole, a new parenteral cephalosporin antibiotic, was administered to 23 newborn infants with pustular skin infection due to Staphylococcus aureus for an average duration of 7.5 days. All the patients improved clinically. Elevation of serum glutamic oxaloacetic transaminase and eosinophilia were observed in nine infants each transiently during treatment. There were no abnormalities of renal functions and Coombs' test results remained negative. The levels of cefamandole in serum after either intravenous or intramuscular administration were higher and the mean life was longer than those previously reported in older infants, children, and adults.
D002435:Cefamandole / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D002511:Cephalosporins / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000378:metabolism; D007700:Kinetics; D008297:Male; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy
D002511:Cephalosporins; D002435:Cefamandole